|
SG10202108118RA
(en)
|
2001-11-13 |
2021-08-30 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
EP3567106A1
(en)
|
2010-04-23 |
2019-11-13 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US9272053B2
(en)
|
2010-04-23 |
2016-03-01 |
University Of Massachusetts |
AAV-based treatment of cholesterol-related disorders
|
|
US9226976B2
(en)
|
2011-04-21 |
2016-01-05 |
University Of Massachusetts |
RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
US10815285B2
(en)
*
|
2011-07-01 |
2020-10-27 |
University Of South Florida |
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
|
|
KR102057540B1
(ko)
*
|
2012-02-17 |
2019-12-19 |
더 칠드런스 호스피탈 오브 필라델피아 |
세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
US9695443B2
(en)
*
|
2012-05-25 |
2017-07-04 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Vector for the selective silencing of a gene in astrocytes
|
|
JP6417322B2
(ja)
*
|
2012-06-21 |
2018-11-07 |
アソシアシオン・アンスティテュ・ドゥ・ミオロジーＡｓｓｏｃｉａｔｉｏｎ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｍｙｏｌｏｇｉｅ |
遺伝子治療ベクターの広範な遺伝子送達
|
|
BR112015002168A2
(pt)
|
2012-08-01 |
2017-11-07 |
Nationwide Childrens Hospital |
liberação intratecal de vírus 9 adeno-associado recombinante
|
|
WO2014043480A1
(en)
*
|
2012-09-13 |
2014-03-20 |
Crystal Ronald G |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
US9539307B2
(en)
|
2012-09-17 |
2017-01-10 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
FI3889173T3
(fi)
|
2013-02-15 |
2023-10-02 |
Bioverativ Therapeutics Inc |
Optimoitu tekijä viii:n geeni
|
|
CA2905952A1
(en)
*
|
2013-03-13 |
2014-10-02 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
CA3126082A1
(en)
|
2013-03-14 |
2014-09-18 |
Universite Laval |
Use of electroretinography (erg) for the assessment of psychiatric disorders
|
|
JP6591956B2
(ja)
|
2013-03-15 |
2019-10-16 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｍｐｓ１を治療するための組成物および方法
|
|
KR20160010526A
(ko)
*
|
2013-05-15 |
2016-01-27 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
|
|
PT3024498T
(pt)
|
2013-07-22 |
2020-03-06 |
Childrens Hospital Philadelphia |
Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos
|
|
PT3024497T
(pt)
*
|
2013-07-26 |
2021-08-23 |
Univ Iowa Res Found |
Métodos e composições para o tratamento de doenças cerebrais
|
|
RS63942B1
(sr)
|
2013-08-27 |
2023-02-28 |
Res Inst Nationwide Childrens Hospital |
Proizvodi i postupci za lečenje amiotrofične lateralne skleroze
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
WO2015060722A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
AU2014346987A1
(en)
|
2013-11-05 |
2016-06-23 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
|
|
CN105765066B
(zh)
|
2013-11-29 |
2018-12-14 |
宝生物工程株式会社 |
用于定量腺伴随病毒的方法
|
|
MY184796A
(en)
*
|
2013-12-11 |
2021-04-22 |
Sumitomo Chemical Co |
Method for manufacturing ciliary marginal zone-like structure
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
*
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
CA3276269A1
(en)
|
2014-03-18 |
2026-03-02 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
EP3137497B2
(en)
|
2014-05-02 |
2025-03-05 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
RU2020140209A
(ru)
*
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN112410338A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
EP4344741A3
(en)
*
|
2014-11-21 |
2024-08-28 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
US10876134B2
(en)
|
2014-12-16 |
2020-12-29 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
US10450563B2
(en)
|
2015-02-10 |
2019-10-22 |
Genzyme Corporation |
Variant RNAi
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
ES2836258T3
(es)
*
|
2015-03-10 |
2021-06-24 |
Univ Columbia |
Construcciones de vectores virales adenoasociados de GLUT1 recombinante y métodos relacionados para restaurar la expresión de GLUT1
|
|
US11046955B2
(en)
*
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
IL302965B2
(en)
*
|
2015-05-29 |
2025-12-01 |
Univ Pennsylvania |
Compositions and methods for degradation of misfolded proteins
|
|
PT3313991T
(pt)
|
2015-06-23 |
2024-09-27 |
Childrens Hospital Philadelphia |
Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
|
|
WO2017005806A1
(en)
*
|
2015-07-07 |
2017-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
|
|
US10047377B2
(en)
*
|
2015-09-22 |
2018-08-14 |
Loyola University Of Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
US10597655B2
(en)
*
|
2015-09-22 |
2020-03-24 |
Loyola University Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017060510A1
(en)
*
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of alzheimer's disease
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
EP3364996B1
(en)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
EP3875593A1
(en)
|
2015-12-11 |
2021-09-08 |
California Institute of Technology |
Targeting peptides for directing adeno-associated viruses (aavs)
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
AU2017215211C1
(en)
|
2016-02-03 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP3436078B1
(en)
*
|
2016-03-31 |
2021-10-27 |
University of Cincinnati |
Methods and compositions for the treatment of als
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
AU2017250298B2
(en)
|
2016-04-15 |
2024-10-03 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
WO2017197355A2
(en)
|
2016-05-13 |
2017-11-16 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
KR20220108216A
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
SG11201809699XA
(en)
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
KR102621134B1
(ko)
*
|
2016-07-26 |
2024-01-04 |
코넬 유니버시티 |
알데히드 데히드로게나제 결핍의 치료를 위한 유전자 요법
|
|
SG10201913002QA
(en)
|
2016-08-15 |
2020-03-30 |
Genzyme Corp |
Methods for detecting aav
|
|
CN110650673B
(zh)
|
2016-08-30 |
2024-04-09 |
加利福尼亚大学董事会 |
用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017336440B2
(en)
|
2016-09-28 |
2022-06-02 |
Cohbar, Inc. |
Therapeutic MOTS-c related peptides
|
|
EP4652926A3
(en)
|
2016-10-12 |
2026-03-18 |
Bioverativ USA Inc. |
Anti-c1s antibodies and methods of use thereof
|
|
CA3040483A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
US11116852B2
(en)
|
2016-11-09 |
2021-09-14 |
Precigen, Inc. |
Frataxin expression constructs
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
EA201992358A1
(ru)
|
2017-04-03 |
2020-03-24 |
Инкоудид Терапьютикс, Инк. |
Тканеселективная экспрессия трансгена
|
|
WO2018191450A2
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University Hospital |
Gene therapy for aadc deficiency
|
|
SG11201909870SA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
EP3634978A1
(en)
|
2017-06-07 |
2020-04-15 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
EP3676385A1
(en)
|
2017-07-06 |
2020-07-08 |
The Trustees of The University of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
TWI832036B
(zh)
|
2017-08-03 |
2024-02-11 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
PE20201264A1
(es)
|
2017-09-20 |
2020-11-19 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adenoasociados y metodos de uso de estas
|
|
JP7449223B2
(ja)
|
2017-09-22 |
2024-03-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉ型を治療するための遺伝子療法
|
|
US11739330B2
(en)
|
2017-09-22 |
2023-08-29 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
IL273394B2
(en)
|
2017-09-22 |
2025-04-01 |
Genzyme Corp |
RNAI variant
|
|
MX2020003042A
(es)
*
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
EP3668997A4
(en)
*
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
CN112553210B
(zh)
|
2017-10-03 |
2024-09-24 |
普利维尔治疗公司 |
用于溶酶体障碍的基因疗法
|
|
CA3078501A1
(en)
|
2017-10-03 |
2019-04-11 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
BR112020006633A2
(pt)
|
2017-10-03 |
2020-10-06 |
Prevail Therapeutics, Inc. |
terapias genéticas para distúrbios lisossômicos
|
|
US11192944B2
(en)
|
2017-10-11 |
2021-12-07 |
Bioverativ Usa Inc. |
Methods of inducing complement activity
|
|
US12441998B2
(en)
*
|
2017-10-12 |
2025-10-14 |
The Trustees Of Columbia University In The City Of New York |
SLC2A1 lncRNA as a biologic and related treatments and methods
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
ES2946747T3
(es)
|
2017-11-27 |
2023-07-25 |
4D Molecular Therapeutics Inc |
Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis
|
|
AU2018375164B2
(en)
|
2017-11-30 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for Mucopolysaccharidosis IIIA
|
|
EA202091352A1
(ru)
|
2017-11-30 |
2020-08-27 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Генотерапия мукополисахаридоза iiib
|
|
JP7401432B2
(ja)
|
2017-12-01 |
2023-12-19 |
エンコーデッド セラピューティクス， インコーポレイテッド |
操作されたｄｎａ結合タンパク質
|
|
EP3768386A4
(en)
|
2018-03-23 |
2022-04-13 |
University of Massachusetts |
GENE THERAPY FOR THE TREATMENT OF BONE DISORDERS
|
|
WO2019195423A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
WO2019195444A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
CA3099958A1
(en)
|
2018-04-16 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
US12129476B2
(en)
|
2018-04-27 |
2024-10-29 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of AADC viral vectors
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3794126A1
(en)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
WO2020010249A1
(en)
*
|
2018-07-06 |
2020-01-09 |
The Regents Of The University Of California |
Novel method to engineer translantable human tissues
|
|
CN120843603A
(zh)
|
2018-07-11 |
2025-10-28 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
|
CA3108324A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Cornell University |
Gene therapy methods to control organ function
|
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
CA3108526A1
(en)
|
2018-08-03 |
2020-02-06 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
|
EP3844285A4
(en)
*
|
2018-08-30 |
2022-06-29 |
Rowan University |
Methods of treating or preventing amyotrophic lateral sclerosis
|
|
SG11202103102WA
(en)
|
2018-09-26 |
2021-04-29 |
California Inst Of Techn |
Adeno-associated virus compositions for targeted gene therapy
|
|
CN113383010B
(zh)
|
2018-09-28 |
2025-09-09 |
沃雅戈治疗公司 |
具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
JP2022512621A
(ja)
|
2018-10-05 |
2022-02-07 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ産生タンパク質をコードする操作された核酸コンストラクト
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3867389A1
(en)
|
2018-10-15 |
2021-08-25 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
JP7590968B2
(ja)
|
2018-12-05 |
2024-11-27 |
アビオナ・セラピュ―ティクス・インコーポレイテッド |
遺伝子送達のための組み換えアデノ随伴ウイルスベクター
|
|
CA3123600A1
(en)
*
|
2018-12-21 |
2020-06-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
CN113518784A
(zh)
|
2019-01-28 |
2021-10-19 |
科巴公司 |
治疗性肽
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US12491264B2
(en)
|
2019-03-04 |
2025-12-09 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
KR20220006527A
(ko)
|
2019-04-10 |
2022-01-17 |
프리베일 테라퓨틱스, 인크. |
리소좀 장애에 대한 유전자 요법
|
|
CN113924313A
(zh)
*
|
2019-04-10 |
2022-01-11 |
马萨诸塞大学 |
因子h载体及其用途
|
|
WO2020210592A1
(en)
*
|
2019-04-12 |
2020-10-15 |
University Of Massachusetts |
Recombinant aav gene therapy for ngyl1 deficiency
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
MX2021013266A
(es)
|
2019-04-29 |
2021-11-17 |
Univ Pennsylvania |
Nuevas capsides de aav y composiciones que las contienen.
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020243651A1
(en)
|
2019-05-29 |
2020-12-03 |
Encoded Therapeutics, Inc. |
Compositions and methods for selective gene regulation
|
|
KR20220016100A
(ko)
*
|
2019-05-31 |
2022-02-08 |
유니버시타트 아우토노마 데 바르셀로나 |
인슐린 유전자 요법
|
|
GB201907882D0
(en)
|
2019-06-03 |
2019-07-17 |
Cyprus Foundation For Muscular Dystrophy Res |
Methods
|
|
EP3983077A4
(en)
*
|
2019-06-17 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
US20220281922A1
(en)
|
2019-08-02 |
2022-09-08 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
GB2587319A
(en)
*
|
2019-08-12 |
2021-03-31 |
Healing Genes Llc |
Genetic construct
|
|
WO2021041485A1
(en)
|
2019-08-26 |
2021-03-04 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2021041489A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
US12403164B2
(en)
|
2019-09-30 |
2025-09-02 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
AU2020367532A1
(en)
|
2019-10-17 |
2022-05-12 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
|
|
KR20220083708A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
Aav 전달 카세트
|
|
CN113614225A
(zh)
*
|
2019-12-17 |
2021-11-05 |
耐克基因有限责任公司 |
细小病毒载体及其制备方法和用途
|
|
JP7839733B2
(ja)
*
|
2020-01-10 |
2026-04-02 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
脳腫瘍を処置するための血液脳関門を横断する免疫療法剤を送達するための方法および組成物
|
|
JP2023513004A
(ja)
|
2020-01-29 |
2023-03-30 |
ジェンザイム・コーポレーション |
眼科遺伝子療法のための改変されたアデノ随伴ウイルスカプシドタンパク質およびその使用方法
|
|
WO2021177116A1
(ja)
|
2020-03-02 |
2021-09-10 |
国立大学法人群馬大学 |
ミクログリア選択的遺伝子発現ベクター
|
|
JP7830341B2
(ja)
|
2020-03-26 |
2026-03-16 |
ディアメンティス・インコーポレイテッド |
網膜信号データを処理し、状態を識別するためのシステムおよび方法
|
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
|
GB202005732D0
(en)
*
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
BR112022021964A2
(pt)
*
|
2020-04-28 |
2023-03-14 |
Pfizer |
Ácidos nucleicos modificados que codificam aspartoacilase (aspa) e vetores para terapia gênica
|
|
CA3177407A1
(en)
|
2020-05-12 |
2021-11-18 |
James M. Wilson |
Compositions for drg-specific reduction of transgene expression
|
|
AU2021273447B2
(en)
|
2020-05-13 |
2026-03-05 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
KR20230074703A
(ko)
|
2020-06-24 |
2023-05-31 |
바이오버라티브 테라퓨틱스 인크. |
유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
US20230293730A1
(en)
*
|
2020-08-05 |
2023-09-21 |
Hangzhou Exegenesis Bio Ltd. |
Nucleic acid constructs and uses thereof for treating spinal muscular atrophy
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
MX2023002016A
(es)
|
2020-08-19 |
2023-06-26 |
Sarepta Therapeutics Inc |
Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
JP7853297B2
(ja)
*
|
2020-11-04 |
2026-04-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｉｌｄ、ｐｆ－ｉｌｄおよびｉｐｆ治療用ウイルスベクターおよび核酸
|
|
WO2022132984A1
(en)
*
|
2020-12-18 |
2022-06-23 |
Duke University |
Compositions for and methods of enhancing spinal cord tissue regeneration
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240158811A1
(en)
*
|
2021-03-11 |
2024-05-16 |
Temple University-Of The Commonwealth System Of Higher Education |
Noninvasive AAV Vectors For Highly Efficient Gene Delivery To The Nervous System
|
|
WO2022247917A1
(zh)
|
2021-05-28 |
2022-12-01 |
上海瑞宏迪医药有限公司 |
衣壳变异的重组腺相关病毒及其应用
|
|
WO2023279108A1
(en)
*
|
2021-07-01 |
2023-01-05 |
Bridgebio Gene Therapy Research, Inc. |
Gene therapy for galactosemia
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4415746A1
(en)
|
2021-10-12 |
2024-08-21 |
Bridgebio Gene Therapy LLC |
Methods and compositions for treating leukodystrophies
|
|
IL311861A
(en)
|
2021-11-02 |
2024-06-01 |
Voyager Therapeutics Inc |
Aav capsid variants and uses thereof
|
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
US20250346920A1
(en)
|
2022-01-25 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
JP2025507352A
(ja)
|
2022-02-09 |
2025-03-18 |
ディアメンティス・インコーポレイテッド |
網膜刺激および／または網膜信号データの収集のためのシステムと方法
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
JP2025513851A
(ja)
|
2022-04-12 |
2025-04-30 |
ジェンザイム・コーポレーション |
遺伝子治療のためのｉｒａｋ４モジュレーターの使用
|
|
EP4508428A1
(en)
|
2022-04-12 |
2025-02-19 |
Genzyme Corporation |
Dendritic cell assay for innate immunogenicity to gene therapy agents
|
|
AU2023252915A1
(en)
|
2022-04-12 |
2024-11-28 |
Genzyme Corporation |
Use of irak4 modulators for gene therapy
|
|
CA3250230A1
(en)
*
|
2022-04-22 |
2023-10-26 |
The General Hospital Corporation |
Human ependyma-specific promoter and uses thereof
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024027632A1
(en)
*
|
2022-08-01 |
2024-02-08 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Novel plasmid backbone to reduce dna impurities in raav preparation
|
|
US20260085328A1
(en)
|
2022-09-08 |
2026-03-26 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CN120019071A
(zh)
|
2022-09-15 |
2025-05-16 |
沃雅戈治疗公司 |
Tau结合化合物
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025158385A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Pegylated il-2 for suppressing adaptive immune response to gene therapy
|
|
TW202546230A
(zh)
|
2024-01-26 |
2025-12-01 |
美商健臻公司 |
靶向ｓｎｃａ之人工ｍｉｃｒｏｒｎａ
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|
|
WO2025235643A1
(en)
|
2024-05-08 |
2025-11-13 |
Genzyme Corporation |
Profiling of gene therapy agents
|